Skip to main content
Premium Trial:

Request an Annual Quote

Cambridge Antibody Files to List ADRs on the Nasdaq

NEW YORK, April 4 – Cambridge Antibody Technology of Melbourn, UK, said Wednesday it had filed a request with the US Securities and Exchange Commission to list American Depositary Receipts on the Nasdaq.

Rowena Gardner, head of corporate communications at CAT, said the company, which trades on the London Stock Exchange, decided to list ADRs on the Nasdaq in order to better service investors.

“Forty percent of our investors are in the states,” Gardner said.

She said she did not know when the ADRs would be listed, but added that she believed the company was towards the end of the regulatory process.

CAT uses develops human monoclonal antibodies for drug discovery and development and is also in agreements to develop protein chips through collaborations with Zyomyx and Oxford Glycosciences.

The company raised 41 million pounds ($58.8 million) in its March 1997 initial public offering and 93 million pounds in a secondary offering in March last year.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.